Key Drivers
- High gross margin
- Q4 profitability
- Large annual losses
AIAI Summary
Liquidia's YUTREPIA launch has transformed it into a high‑gross‑margin, early commercial business that can rapidly de‑risk valuation if it sustains repeatable prescription growth and payer coverage, but upside is highly conditional on resolving United Therapeutics litigation, securing Medicare Part D access, and preserving cash against a thin liquidity buffer.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Q4 profitability
- •Large annual losses
LQDA shows strong unit economics and ample cash with a profitable Q4, but steep full‑year operating losses, excessive OPEX, minimal equity cushion and a sky‑high valuation leave it financially risky.
Price Behavior
Key Price Behavior Insights:
- •Above SMA
- •Failed breakout
- •Volatile swings
LQDA is neutral-to-cautiously-bullish over the last month — trading above the 21-day SMA (support ~mid–high $34s) after a recovery from the late‑Feb low but failing to clear the Mar‑10 peak, so upside requires a decisive break above that recent high while a drop below the SMA would turn short-term bias bearish.
Sharp swing from late‑Feb low to
Sentiment & News
Key News Insights:
- •YUTREPIA market share
- •Analyst upgrades
- •Institutional flows
Liquidia's YUTREPIA launch is driving rapid market-share gains, improving profitability and analyst upgrades amid mixed short-term stock reactions and notable institutional trading.
Continued YUTREPIA uptake and pipeline progress likely support sustained revenue growth and valuation upside, though short-term volatility may persist
Similar Companies in Healthcare
Other companies in the same sector with AI ratings